$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Despite advancements in biomedical research, developing physiologically relevant in vitro assays remains challenging. An ideal assay should accommodate a diverse range of cell types, treatment formulations, timescales, commercial instrumentation, and analytical readouts to meet the needs of researchers across various disciplines. However, due to the lack of suitable tools, researchers often rely on simplistic models, such as 2D monolayers of immortalized cell lines, which fail to recapitulate the complexity and clinical relevance, particularly in cancer research1,2. To address this, large-scale tumor biobanking and clinician collaboration have driven the development of high-fidelity in vitro models such as patient-derived tumor organoids (PDOs), which retain more patient-specific genetic and therapeutic profiles compared to cell lines3,4,5. Meanwhile, advancements in laboratory automation and drug discovery demand platforms that integrate seamlessly into high-throughput workflows. While existing platforms address either biological fidelity or scalability, few have been able to resolve both challenges simultaneously6,7,8. Developing automated, high-throughput models that replicate key disease features is crucial for advancing biomedical research and accelerating data generation for translational applications.
Numerous emerging models aim to address the challenges associated with culturing specialized cell types, such as PDOs, with high throughput (Figure 1). Standard platforms, where organoids are mixed with hydrogel in 96- or 384-well plates, present several limitations: (i) high cell-gel volume leads to inconsistent nutrient access, (ii) well meniscus curvature creates imaging artifacts and cellular gradients, (iii) hydrogel seeding lacks uniformity across batches and personnel, (iv) incompatibility with automated fabrication and automated microscopy, and (v) the use of extracellular matrix (ECM) that is typically soft and fragile risks sample destruction at physiological tissue densities or incorporation of contractile cell types1,9. Currently, the majority of plate-based PDO studies are conducted either by manually seeding the cell-gel into the plate10,11, or a gel-overlay method, where the hydrogel is diluted with a less viscous medium, and cells are centrifuged to the well bottom to place them in the appropriate optical plane12,13. Both approaches fail to provide mechanical support for long-term culture. Based on our previous observations (unpublished data), commercial hydrogel mixed with cells in standard well plates contracts from the surfaces of the well for 9 out of 12 wells over 12 days, while the gel-overlay method lacks physiological cell-matrix interactions. In addition, the resulting cultures cannot be maintained over long periods due to space limitations within the well and are incompatible with assays that require a high reagent-to-cell-medium ratio14,15,16. These practical barriers hinder the adoption of 3D models and limit experimental reproducibility across the field.

Figure 1: Assessment of culture models based on scalability and biological relevance. The relative positioning of various in vitro and in vivo culture systems along scalability (y-axis), defined by plate throughput, and biological relevance (x-axis), highlighting trade-offs between throughput potential and physiological fidelity. Please click here to view a larger version of this figure.
Motivated by these challenges, the high porosity and mechanical reinforcement of a thin cellulose scaffold were leveraged to develop the Scaffold-supported Platform for Organoid-based Tissues (SPOT), available in both 96- and 384-well formats. SPOT incorporates a polymer pre-patterned scaffold using a previously developed infiltration method17 that matches the plate layout, enabling precise cell-gel droplet placement and providing structural support for the hydrogel phase (Figure 2A). Capillary-wicking into the scaffold guides the cell-gel solution, forming a mechanically enforced biocomposite network (Figure 2B). Due to the porous structure of the scaffold, the cell-gel infiltrates and forms a thin layer (approximately 70 µm thick), requiring ten-fold less amount of cell-gel to cover the bottom of the well14. The compatibility of SPOT with seeding pancreatic ductal adenocarcinoma (PDAC) PDOs was also demonstrated by assessing their growth using metabolic assays and image-based measurements. Since its development, SPOT has demonstrated significant versatility and usability for researchers engaged in organoid culture. Additionally, SPOT's design accommodates user-friendly scalability, with reduced reagent volumes and improved imaging capabilities through its flat, meniscus-free microgel geometry, ensuring uniform light penetration and accurate high-content imaging14 (Figure 2C,D). SPOT also supports co-culture with other relevant cell types, such as fibroblasts, to better recapitulate the tumor microenvironment18.

Figure 2: Overview of the 96-SPOT device and image analysis workflow. (A) Schematic representation of SPOT plate fabrication: the device is assembled by collating a commercial bottomless well plate (top), PMMA-patterned scaffold (shown in blue), and polycarbonate film (bottom) using layers of double-sided polyacrylic adhesive (shown in yellow). (B) Cell seeding into scaffold well: cells are suspended in a non-polymerized hydrogel (shown in pink) and pipetted into each well where it infiltrates the scaffold. The hydrogel is then allowed to gel to encapsulate the cells within the scaffold-supported hydrogel. (C) Microscopy: the resulting microtissue can be imaged using automated widefield microscopy. (D) Image-based analysis: Acquired images of fluorescent cells (green) suspended in gel can be analyzed using standard image-analysis pipelines. Representative epifluorescence microscopy image of GFP-expressing KP4 cells in one 96-SPOT well. Scale bar is 500 µm. This figure has been modified from14. Please click here to view a larger version of this figure.
Another advantage of SPOT is that the system can be integrated with an open-source liquid handler, facilitating automated, reproducible fabrication of PDO cultures. This advancement reduces user variability and supports complex experimental designs, including high-throughput drug screening and personalized medicine approaches18. SPOT was also previously shown to be compatible with single-cell-based multiplexed characterization of cellular phenotypes in heterogeneous tumor environments and retrieval of the cells on demand from SPOT by digestion18. These features position SPOT as a versatile tool for screening applications, where longitudinal, high-resolution data are essential for evaluating drug efficacy and cellular behavior under physiologically relevant conditions14,18. By combining these technical innovations, SPOT addresses critical limitations in traditional 3D culture systems.
This protocol provides a comprehensive guide for fabricating SPOT components, assembling plates, and seeding methods for robust and reproducible 3D organoid cultures. It includes detailed instructions for manual plate seeding using a micropipette and automated seeding workflows with a liquid handler, which supports both 96- and 384-well formats. Additionally, this protocol outlines essential quality control measures, such as verifying uniform gel distribution and scaffold integrity, to maintain high experimental standards. Troubleshooting strategies are also provided to address common issues, such as incomplete gel infiltration, evaporation during seeding, and scaffold detachment, equipping researchers with practical solutions to optimize their workflows and achieve reliable outcomes.
SPOT is designed to fill the gaps that traditional organoid assays face, including challenges related to performing assays and media change while preserving gel integrity10,11,12,13. The overall goal of this method is to manufacture a scaffold-supported platform that supports organoid culture over a 12-day period. Additionally, this method also covers generating tissue arrays in SPOT through either manual or liquid handler-assisted seeding to allow users to perform any downstream perturbation, including drug IC50 assays and small molecule screening.